Trial Profile

An Open-label, Parallel-group, Randomized Study to Evaluate the Absolute Bioavailability of Single Dose Subcutaneous Administration of Lecanemab in Healthy Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 28 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lecanemab (Primary) ; Lecanemab (Primary)
Indications Alzheimer's disease
Focus Pharmacokinetics
Sponsors Eisai Inc

Most Recent Events

20 Jul 2023 Results of pooled analysis from NCT05045716 and NCT05533801 comparable efficacy and improved safety compared to lecanemab IV in early Alzheimers disease (AD presented at the Alzheimer's Association International Conference 2023
04 Aug 2022 Results presented at the Alzheimer's Association International Conference 2022
03 Aug 2022 Results presented in an Eisai Co Ltd Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com